Our speakers will explore ground-breaking developments surrounding CRISPR and utilising all genome editing tools as a therapy. It will focus on advancements to overcome ‘off targets’, delivery approaches for in vivo applications and efficacy considerations across patient diversity.CRISPR Therapeutics’ TJ Cradick and Cellectis’ Stefan Scherer will share their clinical trial experiences within therapeutic genome editing applicationsHarvard’s Richard Sherwood will share how to improve CRISPR safety by utilizing machine learningCasebia’s Abraham Scaria will offer delivery guidance to progress in vivo applicationsIn an extremely busy and exciting space it can be hard to pick out the top tool innovations to increase precision and properly discuss clinical challenges, this meeting will facilitate this. It will provide an opportunity with engage with the leading experts who are working on new platforms, leading the clinical trials and have patient insights. It is also a forum to build collaborations to create a clinically and commercially viable, effective and safe approach within gene and cell therapy medicine. ‘CRISPR medicines have the potential to transform the treatment for rare genetic and perhaps common diseases; the challenge for scientists is to demonstrate that these medicines can be both safe and effective’ – Steve Rees, VP of Discovery Biology, AstraZenecaSPEAKERS FROM